U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA failed to inspect a Chinese API manufacturer that may be linked to a recent heparin safety scare because the wrong Chinese firm was entered into an agency database, a compliance official said Feb. 18